Disposition of 7924 shares by John Oyler of BeiGene at 154.2084 subject to Rule 16b-3
| B1GN34 Stock | BRL 42.30 1.46 3.34% |
About 61% of BeiGene's investor base is looking to short. The analysis of current outlook of investing in BeiGene suggests that many traders are alarmed regarding BeiGene's prospects. The current market sentiment, together with BeiGene's historical and current headlines, can help investors time the market. In addition, many technical investors use BeiGene stock news signals to limit their universe of possible portfolio assets.
BeiGene |
Filed transaction by BeiGene Director, Officer: Chief Executive Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
BeiGene Fundamental Analysis
We analyze BeiGene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BeiGene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BeiGene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
BeiGene is rated third in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
BeiGene Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BeiGene stock to make a market-neutral strategy. Peer analysis of BeiGene could also be used in its relative valuation, which is a method of valuing BeiGene by comparing valuation metrics with similar companies.
Peers
BeiGene Related Equities
| BIOM3 | Biomm SA | 6.74 | ||||
| N1VO34 | Novo Nordisk | 6.39 | ||||
| VRTX34 | Vertex Pharmaceuticals | 2.42 | ||||
| T1CH34 | Bio Techne | 1.31 | ||||
| B1NT34 | BIONTECH | 0.87 | ||||
| M1RN34 | Moderna | 0.41 | ||||
| A1SN34 | Ascendis Pharma | 0.00 | ||||
| B1GN34 | BeiGene | 3.34 |
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |